Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusBrief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseA novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent modelsCD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1Gold is a T cell polyclonal activator in BN and LEW rats but favors IL-4 expression only in autoimmune prone BN ratsInduction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent.Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.Determining the breadth of the respiratory syncytial virus-specific T cell responsePulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease.Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infectionFas ligand is required for the development of respiratory syncytial virus vaccine-enhanced diseaseThe number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.Regulation of cytokine production by virus-specific CD8 T cells in the lungs.Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virusVbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVSub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentHLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion proteinRespiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus K(d)M2(82-90) epitope demonstrate similar functional profiles.Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responsesActive and passive immunisation against respiratory syncytial virus.Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccineMajor histocompatibility complex class I gene controls the generation of gamma interferon-producing CD4(+) and CD8(+) T cells important for recovery from friend retrovirus-induced leukemia.Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse.The increased type-1 and type-2 chemokine levels in children with acute RSV infection alter the development of adaptive immune responses.Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challengeRecombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccineGranulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte responseExpression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.Novel pathways in the pathogenesis of respiratory syncytial virus disease.Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantSpecificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseLethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions.
P2860
Q26748856-D0E995D3-2938-49A4-8C73-ECDAB7BA4AE0Q26775152-4A730E39-0137-4A28-AB69-037F1BFD0C56Q27312129-0D1CD2FB-33E2-4A2C-BFFD-382D0E4F834CQ28508535-AB7AACF2-D75A-4BF1-96E8-4359A690DB24Q28574849-40A3DC93-BBA2-4A2B-AB7C-757FBADA6640Q30304128-37963ED7-CEC5-44A2-AB55-0074502805CBQ30305830-9B954062-E1F5-4456-A147-97F9239C2DA5Q30411070-02111758-A25B-41B7-8FB7-398ACC33CB81Q30435871-15AF6AF2-0B9E-4BE7-A2FB-73AA943B06C1Q30436432-E789365A-70BE-4B4D-96D5-39031EA9CEBCQ30436942-2DCA63BF-3972-4230-A366-DE61E330622DQ30437797-9039A932-44F0-4183-A02F-982740B82B8CQ30440743-359E7579-057E-4B70-AE29-329F8ADC3C23Q30441455-211DEC7B-C4CA-4B39-BF3F-D33A71C9B247Q30448968-0C32976B-459E-4331-ACEE-5D11C853F844Q33323372-7CCF9097-C6E4-4DFB-A096-EC8B8EB574EBQ33588916-87DB4013-511B-4B87-92DA-7AF4996B5F43Q33603913-287CE341-40AD-4BCF-8CFD-1A2B4F9C7114Q33648461-2CC6DE1A-2DAF-4B37-9CDF-D953431A9485Q33712590-C70338D8-66AD-4540-B06C-0519009EA60DQ33754172-F9F36056-397C-4F51-885C-C07A7FC0A21DQ33782438-600D7F1D-25D7-4FA2-B71F-4401E8A3CBBBQ33785332-A4259EA8-8D6A-4363-B58E-4080C6176160Q33787180-E1BB9A49-AAC3-4511-8AEE-403BA8E86432Q33797058-602C1388-CFB2-4E73-99ED-7D7B9DFBA0F2Q33807265-39D98C69-66FF-48D9-97A5-8F53A7FD3134Q33809843-5A29FF0E-0DB3-4026-A32F-6180DBF49D2FQ33820420-DBBEACDB-3C90-4E7C-B864-C6C012EB6455Q33825073-0133DBF6-EC12-4025-90B6-DFE7EA9FB2B6Q33840469-A634C9B9-4A51-45EB-98F2-05CAEEE17E56Q33863306-9E08F5A3-0B16-4B18-AF78-81F50E27CCE0Q33870105-A2FA8132-C240-41EA-8D38-C2FFE360992BQ33886159-89D5CF3F-94FE-4292-ABEC-904BF461DE0FQ33908872-1AA2BAA5-900B-4E5C-AD08-9E1C27010468Q33988549-73C948A4-2B09-4896-A2D0-73D10E0582A5Q34151000-4130942B-D5F6-4B87-8076-5FA000C8CBA6Q34182385-A3A0C456-6D12-447A-9441-D07F51225377Q34190602-7DB8BA30-6567-4141-80EA-AFDA8C88200EQ34330690-149BD4BE-B221-4E1D-9CFA-2DFF8CA5C55CQ34432718-B2DD650A-0360-41AD-8C8D-9D55F84D8CDC
P2860
Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@ast
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@en
type
label
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@ast
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@en
prefLabel
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@ast
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@en
P2860
P356
P1476
Virus-specific CD8+ T lymphocy ...... ory syncytial virus infection.
@en
P2093
Braciale TJ
Srikiatkhachorn A
P2860
P304
P356
10.1084/JEM.186.3.421
P407
P577
1997-08-01T00:00:00Z